Article
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Molecular diagnosis & therapy - 1 Oct 2015
Oyaert Matthijs, Demedts Ingel, Boone Elke, Dedeurwaerdere Franceska, Vandorpe Jo, De Laere Emmanuel, Breyne Joke
Abstract excerpt
INTRODUCTION: Mutations in the epidermal growth factor receptor (EGFR) have been reported as predictive markers of tumour response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Although the "common" EGFR mutations have been associated with response to E...
Topics
- Aged
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Erlotinib Hydrochloride
- Exons
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Protein Kinase Inhibitors
- Quinazolines
- Sequence Analysis, DNA
- Treatment Outcome